Benjamin Palleiko Net Worth

The estimated Net Worth of Benjamin L Palleiko is at least $4.41 Milion dollars as of 6 September 2024. Mr. Palleiko owns over 15,625 units of KalVista Pharmaceuticals Inc stock worth over $2,767,389 and over the last 8 years he sold KALV stock worth over $613,234. In addition, he makes $1,028,480 as Chief Financial Officer a Chief Business Officer at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Palleiko KALV stock SEC Form 4 insiders trading

Benjamin has made over 15 trades of the KalVista Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,625 units of KALV stock worth $167,500 on 6 September 2024.

The largest trade he's ever made was exercising 51,031 units of KalVista Pharmaceuticals Inc stock on 17 May 2024 worth over $547,052. On average, Benjamin trades about 11,478 units every 70 days since 2016. As of 6 September 2024 he still owns at least 258,152 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Mr. Palleiko stock trades at the bottom of the page.

Benjamin Palleiko biography

Benjamin L. Palleiko serves as Chief Financial Officer, Chief Business Officer of the Company. Mr. Palleiko joined as Chief Financial Officer of KalVista Limited in August 2016 and was appointed as our Chief Financial Officer in November 2016. Mr. Palleiko was appointed as our Chief Business Officer in addition to his role as Chief Financial Officer in March 2019. Prior to joining us, Mr. Palleiko was co-Founder and CEO of Cielo Therapeutics, Inc. from 2012 until June 2016. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko was an investment banker with the firms Robertson Stephens and SunTrust Bank. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. He served as a Naval Aviator in the U.S. Navy.

What is the salary of Benjamin Palleiko?

As the Chief Financial Officer a Chief Business Officer of KalVista Pharmaceuticals Inc, the total compensation of Benjamin Palleiko at KalVista Pharmaceuticals Inc is $1,028,480. There are 2 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.

How old is Benjamin Palleiko?

Benjamin Palleiko is 54, he's been the Chief Financial Officer a Chief Business Officer of KalVista Pharmaceuticals Inc since 2019. There are 11 older and 6 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Benjamin Palleiko's mailing address?

Benjamin's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... a Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Mr. Palleiko stock trades at KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,